Verastem has been granted a patent for solid forms of a dual RAF/MEK inhibitor, along with pharmaceutical compositions and oral dosage forms. The patent also covers methods for treating cancer and processes for preparing these forms. GlobalData’s report on Verastem gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData


Data Insights Verastem Inc - Company Profile

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on Verastem, Cancer treatment biomarkers was a key innovation area identified from patents. Verastem's grant share as of February 2024 was 27%. Grant share is based on the ratio of number of grants to total number of patents.

Dual raf/mek inhibitor for cancer treatment in solid form

Source: United States Patent and Trademark Office (USPTO). Credit: Verastem Inc

The granted patent (Publication Number: US11873296B2) discloses a solid oral dosage form containing a composition comprising crystalline Form 1 of a compound of Formula II. This Form 1 exhibits specific X-ray power diffraction patterns, characteristic XRPD peaks, and differential scanning calorimetry curves, as detailed in the patent claims. The oral dosage form is also described as substantially free of other solid forms or patterns of the compound of Formula II and certain impurities.

Furthermore, the patent claims cover a method of treating cancer, including melanoma, lung cancer, ovarian cancer, pancreatic cancer, and colorectal cancer, by administering the disclosed oral dosage form to a subject in need. Specific types of cancer, such as low-grade serous ovarian cancer and non-small cell lung cancer, are also mentioned. The composition of the oral dosage form includes a pharmaceutically acceptable carrier like mannitol, along with a lubricant such as magnesium stearate. The patent emphasizes the importance of the specific characteristics of Form 1 in the composition, as well as the limited presence of impurities and other solid forms of the compound of Formula II in the dosage form.

To know more about GlobalData’s detailed insights on Verastem, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies